M Ventures

M Ventures

Last activity: 21.05.2024
Invests in categories: TechnologyPlatformHealthTechDrugDevelopmentBioTechProductArtificial IntelligenceHumanHardware
M Ventures is the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘ KGaA, Darmstadt, Germany's core business areas. From our headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. M Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. M Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck KGaA, Darmstadt, Germany's science and technology base.
Location: Netherlands, North Holland, Amsterdam
Employees: 11-50
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A

Portfolio 77

DateNameWebsiteTotal RaisedLocation
21.05.2024LabGeniuslabgeni.us$79.59MUnited Kin...
16.07.2023DNA SCRIPTdnascript.co$311.17M-
14.04.2023ImmuneBrid...immunebridge.com$12MUnited Sta...
12.03.2023Iktosiktos.ai$16.62MFrance, Il...
21.02.2023Calypso Bi...calypsobiotech.com$55.8MNetherland...
08.11.2022Concerto B...concertobio.com$47.54MUnited Sta...
08.11.2022Micropsi I...micropsi-industries.com$36.08MGermany, B...
08.11.2022Immunitas ...immunitastx.com$97MUnited Sta...
Show more

News 51

29.01.2022Future Fertility Raises Series A to Progress First-In-Class AI-Enabled Fertility Solutions to Improve IVF OutcomesFirst company to develop an AI product to predict egg viability with potential to significantly improve IVF outcomes Financing led by M Ventures with participation from Whitecap Venture Partners
11.12.2021DNA Script Raises $165M in Oversubscribed Series C Financing to Accelerate Commercialization of Enzymatic DNA Printing PlatformNew Funding, Targeted to Accelerate Application Expansion and Platform Commercialization, Brings Total Amount Raised to Date to $280M
11.12.2021Altoida Launches 5-Year Multi-Center Alzheimer’s Study with Eisai and Ionian UniversityResearch collaboration will identify new opportunities in the fight against Alzheimer’s and further validate the predictive diagnostic capabilities of Altoida’s software medical device.
11.12.2021NanoSyrinx announces oversubscribed £6.2M Seed+ funding round to develop its novel biologic delivery platformNanoSyrinx has raised a further £6.2m of seed financing, co-led by incoming Octopus Ventures and existing investor M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck KGaA. Previous investors BioCity and the ...
11.12.2021Merck KGaA, Darmstadt, Germany, Expands Corporate Venture Fund M Ventures with a New Investment of € 600 MillionMerck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the expansion of its strategic, corporate venture capital arm M Ventures
11.12.2021iOmx Therapeutics raises EUR 65 million in Series B roundMartinsried / Munich, Germany, 5 October, 2021: iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the closing of a Series B round tot...
11.12.2021AI Chip Innovator MemryX Hires Veteran Semiconductor Leader Keith Kressin as CEOKeith Kressin appointed as new president and CEO
11.12.2021Altoida Awarded FDA Breakthrough Designation for Development of World’s First Precision Neurology Device for Prediction of Alzheimer's DiseaseBreakthrough Designation will advance the development of industry’s first predictive diagnostic device for conversion to Alzheimer’s disease, backed by two decades of global clinical studies
11.12.2021DNA Script Obtains CE Mark for SYNTAX DNA Printing PlatformDNA Script, a leader in Enzymatic DNA Synthesis (EDS), announced the CE marking of its SYNTAX System, the first EDS-powered benchtop DNA printer
22.11.2021Xilio Therapeutics Announces Closing of Initial Public OfferingXilio Therapeutics, Inc. today announced the closing of its previously announced initial public offering of 7,353,000 shares of its common stock at a price to the public of $16.00 per share
Show more

Mentions in press and media 45

21.05.2024UK’s LabGenius secures €40.9M led by Amsterdam’s M Ventures to advance its drug discovery platformRead this article in: London-based LabGenius, a drug discovery company, announced that it has secured £35M (approximately €40.96M) in a Series B round of funding. The company specialises in using machine learning to discover new therapeutic...
17.04.2024Mosa Meat Secures €40M to Revolutionize Cultivated Beef MarketMosa Meat, a Dutch cultivated meat company, has secured a whopping €40 million in funding to accelerate its mission of transforming the beef industry. The investment will drive production scale-up, cost reduction, and market entry preparati...
16.04.2024Mosa Meat Secures €40M in Funding to Expand Production and Speed Up Launch of Cultivated Meat5 Mins Read Dutch cultivated meat pioneer Mosa Meat has raised €40M ($42.4M) in a new funding round to support the “next phase” of the company’s growth, with a public tasting of its burger imminent ahead of its launch in Singapore. The comp...
16.04.2024Maastricht-based Mosa Meat raises €40 million to help bring cultivated beef to consumers-
05.04.2024Nucleai Revolutionizes Clinical Trials with $14M Funding BoostNucleai, a pioneer in spatial AI biomarkers, has secured a hefty $14M in funding led by M Ventures, the corporate venture arm of Merck KGaA. This investment brings Nucleai's total funding to a solid $60M, fueling their mission to transform ...
04.04.2024Chicago AI-based biotech startup Nucleai raises $14 million led by M Ventures-
03.04.2024Nucleai Secures $14M to Enhance Clinical Trial Enrollment with Spatial AI BiomarkerWhat You Should Know: – Nucleai, a pioneer in spatial AI biomarkers raises $14M in funding led by M Ventures, the corporate venture arm of Merck KGaA. – The investment brings Nucleai’s total funding to $60M and fuels their mission to transf...
03.05.2023Dutch-based Anavo Therapeutics secures €8.5M to systematically drug phosphatases: Know moreLeiden-based Anavo Therapeutics, a company that claims to be the first to systematically drug phosphatases – a rich target space previously considered undruggable for decades, announced that it has raised €8.5M in a Seed extension round of ...
09.03.2023Iktos raises €15.5 million Series A round for AI drug discovery serviceFrench start-up Iktos has raised a €15.5 million Series A round fuelling its launch of its drug discovery platform. Fresh to the Iktos cap table the round is co-led by M Ventures and Debiopharm Innovation Fund, and includes Omnes Capital. I...
17.02.2023Unisers secures $14M to develop defect-detecting tools in chip-making
Show more

Reviews 0

Sign up to leave a review

Sign up Log In